Showing results (1-10 of 316) with videos related to
Sort By:
Pageof 32
Cancers|June 2, 2021
Current and Novel Alkylators in Multiple MyelomaFredrik Schjesvold, Albert OriolEuropean Journal of Haematology|June 20, 2020
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019Fredrik SchjesvoldJournal of Bone Oncology|April 17, 2025
Treatment of myeloma bone disease: When, how often, and for how long?Michael Tveden Gundesen, Fredrik Schjesvold, Thomas LundFrontiers in Immunology|August 20, 2024
Advances and challenges in anti-cancer vaccines for multiple myelomaPegah Abdollahi, Hanne Marie Norseth, Fredrik SchjesvoldEuropean Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.Expert Review of Hematology|March 18, 2020
A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myelomaAlbert OriolFuture Oncology (London, England)|March 7, 2020
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myelomaFredrik Schjesvold, Pawel Robak, Ludek Pour, et al.Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.Cancer Research|June 4, 2015
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor AntigensAnders Aune Tveita, Fredrik Schjesvold, Ole Audun Haabeth, et al.Pageof 32